Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
Authors
Keywords
Cariprazine, Aripiprazole, Bifeprunox, Dopamine receptor, Cocaine self-administration, Cocaine seeking, Relapse, Antipsychotic, Antimanic
Journal
PSYCHOPHARMACOLOGY
Volume 226, Issue 2, Pages 285-293
Publisher
Springer Nature
Online
2012-11-08
DOI
10.1007/s00213-012-2906-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bifeprunox: a partial agonist at dopamine D2 and serotonin1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats
- (2011) Angelo Di Clemente et al. ADDICTION BIOLOGY
- Pharmacological Treatments for Cocaine Dependence: Is There Something New?
- (2011) Laurent Karila et al. CURRENT PHARMACEUTICAL DESIGN
- The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects
- (2011) Pradeep J. Nathan et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
- (2011) István Gyertyán et al. NEUROCHEMISTRY INTERNATIONAL
- Aripiprazole maintenance increases smoked cocaine self-administration in humans
- (2011) Margaret Haney et al. PSYCHOPHARMACOLOGY
- The impact of substance use disorders on the course of schizophrenia—A 15-year follow-up study
- (2011) Lasse M. Schmidt et al. SCHIZOPHRENIA RESEARCH
- Influence of Compulsivity of Drug Abuse on Dopaminergic Modulation of Attentional Bias in Stimulant Dependence
- (2010) Karen D. Ersche et al. ARCHIVES OF GENERAL PSYCHIATRY
- Stimulation of dopamine D2/D3 but not D1 receptors in the central amygdala decreases cocaine-seeking behavior
- (2010) Kenneth J. Thiel et al. BEHAVIOURAL BRAIN RESEARCH
- P.3.c.062 The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia
- (2010) A. Bose et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Competitive dopamine receptor antagonists increase the equiactive cocaine concentration during self-administration
- (2010) Andrew B. Norman et al. SYNAPSE
- Striatal Dopamine Responses to Intranasal Cocaine Self-Administration in Humans
- (2009) Sylvia M.L. Cox et al. BIOLOGICAL PSYCHIATRY
- P.2.e.037 The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial
- (2009) M. Knesevich et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation
- (2009) Adeline Etievant et al. NEUROSCIENCE LETTERS
- Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse
- (2009) Matthew W. Feltenstein et al. PSYCHOPHARMACOLOGY
- The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats
- (2008) Xiao-Qing Peng et al. NEUROPHARMACOLOGY
- Controversies in translational research: drug self-administration
- (2008) Margaret Haney et al. PSYCHOPHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started